Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
39
ZCMD Quote, Financials, Valuation and Earnings
Last price:
$0.66
Seasonality move
:
-14.12%
Day range:
$0.56 - $0.66
52-week range:
$0.54 - $2.50
Dividend yield:
0%
P/E ratio:
1,213.69x
P/S ratio:
0.75x
P/B ratio:
1.16x
Volume:
20.2K
Avg. volume:
28.6K
1-year change:
-53.93%
Market cap:
$16.6M
Revenue:
$15.9M
EPS (TTM):
-$2.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZCMD
Zhongchao, Inc.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$130.3M | -$0.23 | 16.92% | -46.43% | $49.49 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZCMD
Zhongchao, Inc.
|
$0.66 | -- | $16.6M | 1,213.69x | $0.00 | 0% | 0.75x |
|
ADAG
Adagene, Inc.
|
$1.99 | $9.22 | $93.7M | -- | $0.00 | 0% | 895.61x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.96 | $4.00 | $19.7M | -- | $0.00 | 0% | 0.56x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.70 | -- | $5.5M | -- | $0.00 | 0% | 1.37x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$19.50 | $49.49 | $2.2B | -- | $0.00 | 0% | 4.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZCMD
Zhongchao, Inc.
|
-- | -0.807 | -- | 5.42x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZCMD
Zhongchao, Inc.
|
-- | -- | -28.4% | -28.4% | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Zhongchao, Inc. vs. Competitors
-
Which has Higher Returns ZCMD or ADAG?
Adagene, Inc. has a net margin of -- compared to Zhongchao, Inc.'s net margin of --. Zhongchao, Inc.'s return on equity of -28.4% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital ZCMDZhongchao, Inc.-- -- $20.7M ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About ZCMD or ADAG?
Zhongchao, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 363.53%. Given that Adagene, Inc. has higher upside potential than Zhongchao, Inc., analysts believe Adagene, Inc. is more attractive than Zhongchao, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZCMDZhongchao, Inc.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is ZCMD or ADAG More Risky?
Zhongchao, Inc. has a beta of -0.138, which suggesting that the stock is 113.82% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ZCMD or ADAG?
Zhongchao, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zhongchao, Inc. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZCMD or ADAG?
Zhongchao, Inc. quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. Zhongchao, Inc.'s net income of -- is lower than Adagene, Inc.'s net income of --. Notably, Zhongchao, Inc.'s price-to-earnings ratio is 1,213.69x while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zhongchao, Inc. is 0.75x versus 895.61x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZCMDZhongchao, Inc.0.75x 1,213.69x -- -- ADAGAdagene, Inc.895.61x -- -- --
-
Which has Higher Returns ZCMD or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to Zhongchao, Inc.'s net margin of -353.92%. Zhongchao, Inc.'s return on equity of -28.4% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital ZCMDZhongchao, Inc.-- -- $20.7M CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About ZCMD or CASI?
Zhongchao, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 316.62%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Zhongchao, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Zhongchao, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZCMDZhongchao, Inc.0 0 0 CASICASI Pharmaceuticals, Inc.0 0 0 -
Is ZCMD or CASI More Risky?
Zhongchao, Inc. has a beta of -0.138, which suggesting that the stock is 113.82% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock ZCMD or CASI?
Zhongchao, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zhongchao, Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZCMD or CASI?
Zhongchao, Inc. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Zhongchao, Inc.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Zhongchao, Inc.'s price-to-earnings ratio is 1,213.69x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zhongchao, Inc. is 0.75x versus 0.56x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZCMDZhongchao, Inc.0.75x 1,213.69x -- -- CASICASI Pharmaceuticals, Inc.0.56x -- $3.1M -$10.9M
-
Which has Higher Returns ZCMD or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to Zhongchao, Inc.'s net margin of -86.16%. Zhongchao, Inc.'s return on equity of -28.4% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital ZCMDZhongchao, Inc.-- -- $20.7M CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About ZCMD or CPHI?
Zhongchao, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Zhongchao, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe Zhongchao, Inc. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZCMDZhongchao, Inc.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is ZCMD or CPHI More Risky?
Zhongchao, Inc. has a beta of -0.138, which suggesting that the stock is 113.82% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock ZCMD or CPHI?
Zhongchao, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zhongchao, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZCMD or CPHI?
Zhongchao, Inc. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Zhongchao, Inc.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Zhongchao, Inc.'s price-to-earnings ratio is 1,213.69x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zhongchao, Inc. is 0.75x versus 1.37x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZCMDZhongchao, Inc.0.75x 1,213.69x -- -- CPHIChina Pharma Holdings, Inc.1.37x -- $756.2K -$651.5K
-
Which has Higher Returns ZCMD or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to Zhongchao, Inc.'s net margin of --. Zhongchao, Inc.'s return on equity of -28.4% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital ZCMDZhongchao, Inc.-- -- $20.7M SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About ZCMD or SVA?
Zhongchao, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Zhongchao, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe Zhongchao, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZCMDZhongchao, Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is ZCMD or SVA More Risky?
Zhongchao, Inc. has a beta of -0.138, which suggesting that the stock is 113.82% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock ZCMD or SVA?
Zhongchao, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. Zhongchao, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios ZCMD or SVA?
Zhongchao, Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. Zhongchao, Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, Zhongchao, Inc.'s price-to-earnings ratio is 1,213.69x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zhongchao, Inc. is 0.75x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZCMDZhongchao, Inc.0.75x 1,213.69x -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns ZCMD or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Zhongchao, Inc.'s net margin of -30.98%. Zhongchao, Inc.'s return on equity of -28.4% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital ZCMDZhongchao, Inc.-- -- $20.7M ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About ZCMD or ZLAB?
Zhongchao, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.49 which suggests that it could grow by 153.79%. Given that Zai Lab Ltd. has higher upside potential than Zhongchao, Inc., analysts believe Zai Lab Ltd. is more attractive than Zhongchao, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZCMDZhongchao, Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is ZCMD or ZLAB More Risky?
Zhongchao, Inc. has a beta of -0.138, which suggesting that the stock is 113.82% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock ZCMD or ZLAB?
Zhongchao, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zhongchao, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZCMD or ZLAB?
Zhongchao, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Zhongchao, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Zhongchao, Inc.'s price-to-earnings ratio is 1,213.69x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zhongchao, Inc. is 0.75x versus 4.74x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZCMDZhongchao, Inc.0.75x 1,213.69x -- -- ZLABZai Lab Ltd.4.74x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Sell
50
TGL alert for Dec 8
Treasure Global, Inc. [TGL] is up 7.35% over the past day.
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 47.5% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 10.15% over the past day.
